Allarity Therapeutics vs Lisata Therapeutics
ALLR and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLR and LSTA compare
Allarity Therapeutics is the larger company, worth 1.4 times as much as Lisata Therapeutics ($13.9M against $9.8M).
Lisata Therapeutics scores higher on the StockData Score (6 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLR | LSTA |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | $9.8M |
| Share price | $0.875 | $1.09 |
| Change, 1 year | −26.5% | −47.3% |
| Change, 5 years | – | −92.6% |
| Beta (5Y) | 1.41 | −1.65 |
| Employees | 8 | 21 |
| StockData Score | ||
| Total score | 1 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 98.2× |
| P/B | 3.9× | 1.2× (better) |
| FCF yield | – | −125% |
| Growth | ||
| Revenue growth (TTM) | – | −90.7% |
| Profitability | ||
| Operating margin | – | −16427% |
| Net margin | – | −14621% |
| FCF margin | – | −12323% |
| Return on equity | −157% | −99.9% (better) |
| Return on invested capital | −957% (better) | −1645% |
| Financial health | ||
| Debt / equity | 5.90 (better) | 0.00 |
| Interest coverage | −10.1× | – |
| Current ratio | 1.11 | 3.69 (better) |
| Altman Z-score | −6.64 (better) | −74.72 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | 6.4% (better) | −6.0% |
| Shareholder yield | 6.4% (better) | −6.0% |
| Ownership | ||
| Held by institutions | 8.1% | 12.1% |
| Held by insiders | 6.3% | 11.6% |
| Short interest, % of float | 1.5% | 0.43% |
Go deeper
- ALLR stock overview
- ALLR income statement
- ALLR valuation and score
- LSTA stock overview
- LSTA income statement
- LSTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.